隐性自身抗体轴与缺血性中风中的血管脆弱性相关:综合统计和机器学习分析
Tomohiro Sugiyama1,2, Yoichi Yoshida1,2, Takaki Hiwasa1
1Department of Neurological Surgery, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
International journal of molecular sciences
|March 14, 2026
概括
血清自身抗体可能提供关于中风血管风险的见解,即使它们不会显著改善预测模型. 这些生物标志物捕获血管和免疫应激的生物信号,可能有助于了解中风易感性.
科学领域:
- 心血管研究研究心血管研究
- 免疫学 免疫学 免疫学
- 生物标志物发现发现
背景情况:
- 缺血性中风是全球死亡和残疾的主要原因.
- 识别高血管风险的个体需要改进策略.
- 血清自身抗体在预测中风风险中的作用尚未完全理解.
研究的目的:
- 调查血清特定自身抗体 (抗PDCD11,抗DNAJC2,抗PAI-1) 对缺血性中风的预测价值.
- 探索这些自身抗体的综合生物学意义,超出已确定的临床风险因素.
- 评估机器学习模型的性能,包括用于预测中风风险的抗体标记物.
主要方法:
- 分析了833名参与者 (中风患者和对照组).
- 血清自身抗体的量化和逻辑回归和机器学习模型的构建.
- 使用交叉验证,校准和重新分类指数评估模型性能.
- 使用PCA,无监督聚类和SHAP分析探索生物结构.
主要成果:
- 临床模型显示出出色的中风区分 (AUC~0.92).
- 添加抗体标志物并没有显著改善整体模型性能或重新分类.
- SHAP分析表明抗体标志物是有影响力的贡献者,PCA揭示了与中风风险相关的主导抗体成分.
- 无监督聚类确定了一个高风险子组,其抗体水平较高.
结论:
- 潜在的抗体轴与中风中的血管脆弱性有关.
- 自体抗体分析捕获了血管和免疫应激的综合生物信号.
- 虽然不会提高全球预测,但自身抗体可能会改善中风易感性的生物特征,需要潜在的验证.
相关概念视频
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
692
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
692
Ischemic Heart Disease: Overview
3.8K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.8K
Atherosclerosis I: Introduction
1.8K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.8K
Peripheral Artery Disease I: Introduction
549
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
549
Vascular Spasm
4.5K
The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last...
4.5K
Atherosclerosis III: Management
558
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
558


